|
SYNTHETIC MIMOTOPES
OF b2-GPI-SPECIFIC ANTI-CARDIOLIPIN ANTIBODIES.
Stephen M. Coutts, et al.
Presented at the
Australasian Society of Clinical Immunology and Allergy and Immunology
Society Meeting
Oct. 30-Nov. 3, 1995
Sydney, Australia.
A PILOT STUDY
OF LJP 394, A NOVEL THERAPEUTIC AGENT FOR THE TREATMENT OF SYSTEMIC
LUPUS ERYTHEMATOSUS
M.H.Weisman, et al.
Presented at the
American College of Rheumatology Conference
October 21-26, 1995
San Francisco, CA
SCREENING OF
RANDOM PEPTIDE PHAGE DISPLAY LIBRARIES WITH ANTICARDIOLIPIN ANTIBODIES.
Edward J. Victoria, et al.
Presented at the
Western Biotech Conference
Oct. 18-21, 1995
San Diego, CA.
SYNTHETIC PEPTIDES
WITH BINDING SPECIFICITY FOR ANTIPHOSPHOLIPID ANTIBODIES.
David S. Jones, et al.
Presented at the
Western Biotech Conference
Oct. 18-21, 1995
San Diego, CA.
LJP 394: A NOVEL CLINICAL CANDIDATE FOR THE TREATMENT OF LUPUS NEPHRITIS.
Marian L. Plunkett, et al.
Presented at the
4th International Conference on Systemic Lupus Erythematosus (SLE)
March 26-31, 1995
Jerusalem, Israel.
|
IMMUNOSPECIFIC
REDUCTION OF ANTIOLIGONUCLEOTIDE ANTIBODY-FORMING CELLS WITH A
TETRAKIS-OLIGONUCLEOTIDE CONJUGATE (LJP 394), A THERAPEUTIC CANDIDATE
FOR THE TREATMENT OF LUPUS NEPHRITIS.
David S. Jones., et al.
Published in the
Journal of Medicinal Chemistry
1995, 38
|